Daesung Microbiological Labs. Co (036480) Fair Value & Analysis
Healthcare · KR · Market cap 24.7B KRW
Fair value as of: Jul 20, 2026
From 19 valuation models · updated 21 days ago
Share price +2.3% over the past month.
A solid business, but screening 69% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (2,755 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (1,189 KRW to 2,755 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.
How to read this chart
60‑month range 5,590 KRW – 21,665 KRW · fair‑value band 1,189 KRW – 2,755 KRW · the 6,340 KRW price screens above the 1,970 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.
Analysis
Daesung Microbiological Labs. Co (036480) currently trades at 6,340 KRW, while our model-based Fair Value estimate is 1,970 KRW, implying the stock looks roughly 68.9% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Daesung Microbiological Labs. Co generated revenue of 25.9B KRW at a net margin of 2.5%. Revenue declined 2.3% year over year. It earns a return on equity of 1.9%. Net debt stands at 16.2B KRW. Fundamentals as of Jul 20, 2026
Our scenario range runs from 1,189 KRW (bear case) to 2,755 KRW (bull case); at 6,340 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -69%, 036480 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 19 models by family
Widest divergence: Asset-Based (6,245 KRW) versus Growth DCF (194.06 KRW). Highest evidence: Growth DCF (80).
Notify me when 036480 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 31
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd.
Full company description
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in Uiwang-si, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Daesung Microbiological Labs. Co reported revenue of 26.0B KRW in FY2025 versus 24.0B KRW in FY2021, a compound +2.0%/yr. Reported net income was 598M KRW in FY2025, compounding −8.8%/yr from FY2021.
036480 screens 69% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Daesung Microbiological Labs. Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Daesung Microbiological Labs. Co (036480) overvalued or undervalued?
What is the fair value of 036480?
What is the quality score of 036480?
What is the revenue of Daesung Microbiological Labs. Co (036480)?
What is the net profit margin of 036480?
Does Daesung Microbiological Labs. Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Daesung Microbiological Labs. Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.